A Systematic Review of Artificial Intelligence‐Based Clinical Decision Support Systems in Prostate Cancer Management
Systematische Übersicht zu KI-basierten Clinical Decision Support Systems im Prostatakarzinom-Management
Healthcare Technology Letters · 2025-01 · 12 (1)
DOI: 10.1049/htl2.70026 ↗Auf einen Blick
Die systematische Übersicht beschreibt 10 Studien zu KI-basierten CDSS beim Prostatakarzinom. Die Leistung war variabel; moderne ML-Modelle schnitten für Risiko- und Überlebensprognosen meist besser ab.
Fragestellung
Welche Entwicklung, Implementierung und Limitationen haben KI-basierte CDSS bei Diagnose, Staging, Behandlung oder Management des Prostatakarzinoms?
Methode
Systematische Übersichtsarbeit nach PRISMA; Suche in PubMed, Scopus, Web of Science und Embase, Update-Suche im Juni 2024; Einbezug von Studien mit Entwicklung und Evaluation KI-basierter CDSS für PCa.
Ergebnisse
10 Studien erfüllten die Kriterien. Aufgaben: Diagnose, Risiko-/Rezidivprognose, Überleben und Optimierung von Radiotherapie-/Brachytherapieplänen. Ein Workflow-CDSS ohne prädiktives Modell verkürzte die Entscheidungszeit um 60 %.
Einschränkungen
Kleine oder heterogene Stichproben, begrenzte Generalisierbarkeit, unvollständige Dateneingaben, wenig externe Validierung/Kalibrierung und Interpretationsprobleme.
Schlussfolgerung der Autor:innen
KI-basierte CDSS beim Prostatakarzinom erscheinen vielversprechend für Diagnose, Prognose und Therapieplanung und können die Effizienz verbessern. Für breitere Anwendung sind bessere Daten, Validierung und klinische Integration nötig.
Kernaussagen
- 10 Studien zu KI-basierten CDSS beim Prostatakarzinom
- Modernes ML oft besser als traditionelle Baselines bei Risiko- und Überlebensprognosen
- Externe Validierung, Kalibrierung und EHR-Integration bleiben unzureichend
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Healthcare Technology Letters, online erschienen am 18.11.2025. Verfasst von Senobar Naderian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Information Technology School of Management and Medical Informatics Tabriz University of Medical Sciences Tabriz Iran. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prostate cancer (PCa) affects over 1.4 million individuals annually and remains one of the leading causes of cancer‐related death globally. Artificial intelligence‐based clinical decision support systems (AI‐CDSS) are increasingly used to improve diagnostic and treatment decisions in PCa management.
Objective
This systematic review aims to evaluate the development, implementation, and limitations of AI‐based CDSS applied to the diagnosing, staging, treatment, or management of PCa.
Method
The review protocol was registered with PROSPERO (ID = CRD42024498335) and adhered to preferred reporting items for systematic reviews and meta‐analyses (PRISMA) guidelines. Using the (population/intervention/comparison/outcome) PICO framework, research questions were formulated to examine system development, AI models applied, adherence to CDSS standards, and integration into clinical decision‐making phases. A systematic search of PubMed, Scopus, Web of Science and Embase retrieved 1137 articles; after removing 173 duplicates, 964 records were screened. A subsequent update search in June 2024 identified no additional papers. Two reviewers independently screened titles and abstracts, full texts, and resolved disagreements through discussion with a third reviewer. Studies were included if they developed and evaluated AI‐based CDSS for PCa with reported performance metrics. Studies were excluded if they did not involve AI‐based CDSS, lacked evaluation data, or did not address clinical decision‐making.
Results
Ten studies met the inclusion criteria. Cohorts ranged from 10 to 1.93 million records. Reported tasks included diagnosis, risk/recurrence prediction, survival estimation, and radiotherapy/ brachytherapy plan optimization. Common models were gradient boosting, neural networks, and deep reinforcement learning (DRL). Performance was variable but modern ML generally outperformed traditional baselines for survival and risk prediction (e.g., AUROC ≈ 0.84 for three‐year recurrence; C‐index up to 0.92 for five‐year progression‐free survival (PFS)). A workflow CDSS without predictive modeling reduced decision‐making time by 60%. Key limitations included small or heterogeneous samples, limited generalizability, inconsistent or incomplete data inputs, scarce external validation/calibration, and interpretability concerns. Core CDSS components were inconsistently implemented.
Conclusions
AI‐based CDSS for PCa show promise for diagnosis, prognosis, and treatment planning and may improve efficiency. However, broader adoption will require high‐quality, multi‐site data; external validation and calibration; interpretable models; and robust integration with EHRs and clinical workflows. Prospective clinical evaluations are needed to confirm patient‐level impact.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Information Technology School of Management and Medical Informatics Tabriz University of Medical Sciences Tabriz Iran.
- Cancer Artificial Intelligence Collaborative Group (CAICG) Universal Scientific Education and Research Network (USERN) Tabriz Iran.
- Urology Department Tabriz University of Medical Sciences Tabriz Iran.
- Tabriz Health Services Management Research Center Tabriz University of Medical Sciences Tabriz Iran.
- Research Center For Integrative Medicine in Aging Aging Research Institute Tabriz University of Medical Sciences Tabriz Iran.
- Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine Tabriz University of Medical Sciences Tabriz Iran.
Zitieren
APA
Naderian, S., Soleimanzadeh, F., Nikniaz, L., Sanaie, S., Sadeghi-Ghyassi, F., & Samad-Soltani, T. (2025). A Systematic Review of Artificial Intelligence‐Based Clinical Decision Support Systems in Prostate Cancer Management. Healthcare Technology Letters, 12(1). https://doi.org/10.1049/htl2.70026
Vancouver
Naderian S, Soleimanzadeh F, Nikniaz L, Sanaie S, Sadeghi-Ghyassi F, Samad-Soltani T. A Systematic Review of Artificial Intelligence‐Based Clinical Decision Support Systems in Prostate Cancer Management. Healthcare Technology Letters. 2025;12(1). doi:10.1049/htl2.70026
BibTeX
@article{Naderian2025,
author = {Naderian, Senobar and Soleimanzadeh, Farzin and Nikniaz, Leila and Sanaie, Sarvin and Sadeghi-Ghyassi, Fatemeh and Samad-Soltani, Taha},
title = {A Systematic Review of Artificial Intelligence‐Based Clinical Decision Support Systems in Prostate Cancer Management},
journal = {Healthcare Technology Letters},
year = {2025},
volume = {12},
number = {1},
doi = {10.1049/htl2.70026}
}
EUVIMED